CardioMech AS Announces $18.5M Series A...
Continue Reading-
Abliva receives positive FDA feedback on its KL1333 development plan
Abliva AB (Nasdaq Stockholm: ABLI) today announced that it has received positive feedback from the…
Continue Reading -
Pipeline Therapeutics Initiates Phase 1/2a Clinical Trial of PIPE-505 in Sensorineural Hearing Loss
PIPE-505 is the first small molecule developed specifically for the treatment of sensorineural hearing loss…
Continue Reading -
Gesynta raises SEK 190 million in round led by Hadean Ventures to accelerate development of first-in-class mPGES-1 inhibitor GS-248 for systemic sclerosis
July 7, 2020, Stockholm Gesynta Pharma AB (‘Gesynta’ or ‘The Company’) a clinical-stage company…
Continue Reading -
€1.9M EU funding takes Nelli® available for all epilepsy patients
Neuro Event Labs (NEL) will use €1.9M EU Horizon 2020 grant to become the standard…
Continue Reading -
Abliva completes the directed issue of MSEK 20 to Hadean Ventures
On April 22, 2020, the Board of Directors of Abliva AB (publ) (“Abliva” or the…
Continue Reading -
Hadean Ventures invests in Themis Bioscience GmbH EUR 40m Series D Financing round
Hadean Ventures invests in Themis Bioscience GmbH EUR 40m Series D Financing round Investment Q2…
Continue Reading -
Hadean Ventures leads 40 million SEK (€3.7 million) investment round into SAGA to advance ultrasensitive cancer liquid biopsies
LUND, Sweden and OSLO, Norway, June 11, 2019 — /B3C Newswire/ — SAGA Diagnostics AB,…
Continue Reading -
Hadean Ventures’ Ingrid Teigland Akay receives Investor of the Year award at the SHE conference
Oslo 6th March, 2019. Today Ingrid Teigland Akay, founder and managing partner at Hadean Ventures,…
Continue Reading
